Suzhou Ribo Life Science Co., Ltd. and its subsidiary Ribocure Pharmaceuticals AB have announced that their novel siRNA drug, RBD5044, has received approval to commence Phase II clinical trials in the European Union. This represents a significant step forward in the development of RNA interference therapies targeting lipid metabolism.<\/p>\n\n\n\n
RBD5044: A Novel siRNA Drug Targeting ApoC3<\/strong><\/p>\n\n\n\n RBD5044 is developed using the RIBO-GalSTARTM liver-targeting technology platform and is designed to decrease ApoC3 levels via siRNA-mediated gene silencing. The upcoming Phase II trial will be a randomized, double-blind, placebo-controlled, multi-center study aimed at evaluating the efficacy and safety of RBD5044 in patients with mixed hyperlipidemia.<\/p>\n\n\n\n Potential Impact on Cardiovascular Disease Risk<\/strong><\/p>\n\n\n\n As a GalNAc-conjugated siRNA drug, RBD5044 effectively and precisely reduces plasma ApoC3 protein levels, a key component in triglyceride-rich atherogenic lipoproteins. Research indicates that plasma ApoC3 levels independently predict coronary events, while genetic studies link ApoC3 loss-of-function mutations and decreased plasma triglyceride levels to reduced cardiovascular disease risk. RBD5044 holds promise for lowering cardiovascular disease risks and may help mitigate recurrent acute pancreatitis in patients with severe hypertriglyceridemia by inhibiting ApoC3 and decreasing plasma triglyceride.<\/p>\n\n\n\n